Iron status predicts prognosis in patients with T2DM, CAD

November 5, 2013
Iron status predicts prognosis in patients with T2DM, CAD

(HealthDay)—Iron status can independently predict long-term outcomes in patients with type 2 diabetes and coronary artery disease (CAD), according to a study published online Oct. 15 in Diabetes Care.

Beata Ponikowska, M.D., Ph.D., from Wroclaw Medical University in Poland, and colleagues measured serum ferritin, transferrin saturation, and soluble transferrin receptor (sTfR) in 287 with type 2 diabetes and stable CAD (average age, 65 years; 78 percent men). Participants were followed for a mean of 45 months.

The researchers found that, during the study period, 21 percent of patients died and 21 percent had cardiovascular hospitalizations. The five-year all-cause mortality rates were strongly predicted by both serum ferritin and sTfR, independent of other variables (including hemoglobin, measures of renal function, inflammation, and neurohormonal activation). The relationship between sTfR and mortality was exponential (adjusted hazard ratio [HR] per 1 log mg/L, 4.24; P = 0.01), while a U-shaped relationship was seen for ferritin and mortality (for the lowest and the highest quintiles versus the middle quintile, respectively: adjusted HRs, 7.18 and 5.12).

"Both low and high (possibly reflecting depleted and excessive iron stores, respectively) along with high serum sTfR (reflecting reduced metabolically available iron) identify patients with type 2 and CAD who have a poor prognosis," the authors conclude.

Several authors disclosed financial ties to the pharmaceutical industry.

Explore further: Skin intrinsic fluorescence tied to coronary artery disease

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Skin intrinsic fluorescence tied to coronary artery disease

August 7, 2012

(HealthDay) -- Skin intrinsic fluorescence (SIF) is significantly associated with coronary artery disease (CAD) in middle-aged adults with a long duration of type 1 diabetes, according to a study published online July 30 ...

Clopidogrel after MI less effective in diabetes patients

September 5, 2012

(HealthDay)—Clopidogrel therapy following a heart attack does less to reduce the risk of death in patients with diabetes than in those without diabetes, according to a study published in the Sept. 5 issue of the Journal ...

Metformin may increase risk of cognitive impairment

September 21, 2013

(HealthDay)—Metformin may increase the risk of cognitive impairment in patients with diabetes; however, calcium supplementation may attenuate this risk, according to research published online Sept. 5 in Diabetes Care.

Recommended for you

Engineered hot fat implants reduce weight gain in mice

August 20, 2015

Scientists at the University of California, Berkeley, have developed a novel way to engineer the growth and expansion of energy-burning "good" fat, and then found that this fat helped reduce weight gain and lower blood glucose ...

Bacteria may cause type 2 diabetes

June 1, 2015

Bacteria and viruses have an obvious role in causing infectious diseases, but microbes have also been identified as the surprising cause of other illnesses, including cervical cancer (Human papilloma virus) and stomach ulcers ...

Promising progress for new treatment of type 1 diabetes

July 30, 2015

New research from Uppsala University shows promising progress in the use of anti-inflammatory cytokine for treatment of type 1 diabetes. The study, published in the open access journal Scientific Reports, reveals that administration ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.